Clinical trials: Relative Bioavailability
Biological Availability
A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a…
- Trial name
- NCT06137703
- Testing
- Zavegepant 100mg non-enteric coated soft gel capsule, Zavegepant 100mg immediate release tablet, Zavegepant 2 x 100mg immediate release tablets
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin, linagliptin \& metformin extended release (XR) and the single tablets…
- Trial name
- NCT02821910
- Testing
- High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed, 1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR, High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasms
Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule
This is a three stage, open label, randomized-sequence, single-crossover Phase 1 study to evaluate the relative bioavailability (BA) and Bioequivalence (BE) of niraparib administered as a tablet formulation compared to the…
- Trial name
- NCT03329001
- Testing
- Niraparib Tablet, Niraparib Capsule
- Where
- 16 sites in United States
- Volunteers
- 236 people
- Sponsor
- Tesaro, Inc.
Healthy
Safety of Single Rising Doses and Relative Bioavailability of BI 691751
To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of single rising doses of BI 691751 in healthy male subjects (part I).
- Trial name
- NCT01843972
- Testing
- BI 691751
- Where
- Germany
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Participants
A Study of LY2940680 in Healthy Participants
This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the safety and side effects of LY2940680 in healthy participants.
- Trial name
- NCT01681186
- Testing
- LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Comparison of the Bioavailability of Diclofenac in a Combination Product (Diclofenac 2% + Capsaicin 0.075% Topical Gel) With Two Diclofenac Only Products, Diclofenac Mono Gel 2% and Voltarol® 12 Hour Emulgel 2.32% Gel, in Healthy Volunteers
The main objective of this study is to assess the relative systemic bioavailability of diclofenac in the presence and absence of capsaicin by comparing the systemic bioavailability of diclofenac from a combination product…
- Trial name
- NCT03074162
- Testing
- Diclofenac Sodium, Diclofenac & Capsaicin, Diclofenac Sodium Topical Gel
- Where
- South Africa
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers
This is a Phase I, open label, randomized, crossover trial to investigate the relative bioavailability of tepotinib in healthy volunteers.
- Trial name
- NCT03021642
- Testing
- Tepotinib test (Treatment Period 1), Tepotinib reference (Treatment Period 2), Tepotinib reference (Treatment Period 1)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Healthy Participants
Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition
This study is intended to estimate the relative bioavailability of a single 500 mg dose of bosutinib when administered as capsule contents mixed with applesauce or yogurt to intact capsules under fed condition in adult healthy…
- Trial name
- NCT04916769
- Testing
- Bosutinib capsule
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Divalproex Sodium Delayed-Release Tablets Under Fasting Conditions
This study will compare the relative bioavailability of 500 mg Divalproex Sodium Delayed-Release Tablets with that of 500 mg Depakote® Tablets following a single oral dose (1 x 500 mg tablets)in healthy subjects under fasting…
- Trial name
- NCT00834639
- Testing
- divalproex sodium, Depakote®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Healthy
DDI Between BI Empagliflozin (10773) and Verapamil
Relative bioavailability of BI 10773 given alone and together with verapamil
- Trial name
- NCT01276301
- Testing
- Verapamil, BI 10773
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants
This is a single dose crossover pharmacokinetic (pharmacokinetics helps in understanding how the drug is changed and eliminated from the body after a participant takes it) study in healthy participants.
- Trial name
- NCT05431153
- Testing
- Single dose of PF-07104091 as Tablet Formulation A (Treatment A), Single dose of PF-07104091 as Tablet Formulation B (Treatment B), Single dose of PF-07104091 as Tablet Formulation C (Treatment C)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Volunteers
Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
The purpose of this study is to assess the bioavailability of dexlansoprazole from a 30 milligram (mg) or 60 mg delayed-release capsule manufactured at Takeda GmbH Plant Oranienburg, Germany (TOB) relative to that of…
- Trial name
- NCT03131895
- Testing
- 30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
A Study in Healthy Men to Test Whether Four Capsules of 25 mg Nintedanib Are Taken up in the Body in the Same Way as One 100 mg Capsule
The main objective of this trial is to investigate the relative bioavailability of 100 mg nintedanib given as four capsules of 25 mg nintedanib compared with one capsule of 100 mg nintedanib.
- Trial name
- NCT04938453
- Testing
- nintedanib 25 mg, nintedanib 100 mg
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Schizophrenia
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of TAK-041: 1. Following oral single and multiple doses in healthy participants. 2.
- Trial name
- NCT02748694
- Testing
- TAK-041
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Neurocrine Biosciences
Healthy
A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
The main objectives of this trial are to investigate the relative bioavailabilities of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1323495 (Test 1, Test 2) following…
- Trial name
- NCT04257032
- Testing
- Rosuvastatin, Rosuvastatin + BI 1323495, Dabigatran etexilate
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease, Healthy Volunteers
Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants
The purpose of this study was to assess the safety, tolerability, and pharmacokinetic (PK) of TAK-071 when administered as single rising dose (SRD) and multiple rising dose (MRD) orally in healthy participants and participants…
- Trial name
- NCT02769065
- Testing
- TAK-071, Donepezil
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Takeda
Parkinson
Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers
Single-centre, open-label, randomised, three-part, two-way crossover study in 84 healthy volunteers. In each part, the study consisted of two consecutive single-dose treatment periods separated by a washout period of at least 14…
- Trial name
- NCT02305277
- Testing
- BIA 9-1067 (clinical micronized, CM), BIA 9-1067 (to-be-marketed, TBM)
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Filariasis
Relative Bioavailability Study of Emodepside IR-tablets and Solution
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov…
- Trial name
- NCT03383523
- Testing
- Emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
HIV Infections
A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254
This is a first time in human (FTIH), 2-period study, to assess the relative bioavailability of a mesylate salt capsule of GSK3640254, compared to a bis- hydrochloride salt capsule of GSK3640254, in healthy subjects, administered…
- Trial name
- NCT03575962
- Testing
- GSK3640254 bis-hydrochloride salt capsule, GSK3640254 Mesylate Salt Capsule
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy
Zaleplon 10 mg Capsules Under Non-Fasting Conditions
The objective of this study is to compare the relative bioavailability of zaleplon 10 mg capsules(manufactured and distributed by TEVA Pharmaceuticals USA) with that of SONATA® 10mg capsules (Wyeth-Ayerst Pharmaceuticals) in…
- Trial name
- NCT00829868
- Testing
- Zaleplon 10 mg Capsules, SONATA® 10 mg capsules
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA